MesoPher Drug Insight and Market Forecast - 2032

“"MesoPher Drug Insight and Market Forecast - 2032" report provides comprehensive insights about MesoPher for malignant pleural mesothelioma (MPM) in the seven major markets. A detailed picture of the MesoPher for MPM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the MesoPher for MPM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the MesoPher market forecast analysis for MPM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in MPM.

Drug Summary:

MesoPher is a product of Amphera BV, comprised of autologous patient dendritic cells (DCs) loaded with PheraLys. This treatment starts by taking blood samples of pleural mesothelioma patients. The dendritic cells are present in the white blood cells of the blood. White blood cells are extracted through a process called leukapheresis. Afterward, patient monocytes are isolated from the leukapheresis product and differentiated ex vivo into immature DCs. The patient's immature DCs are then loaded with PheraLys to create activated, mature DCs, capable of presenting key tumor-associated antigens (TAAs) to the immune system. On returning the activated DCs to the patient, they migrate to the lymph nodes, where they induce an immune response, including NK cells, B cells, and T cells, to attack the tumor (Amphera, 2019).

Currently, this product is being investigated in the DENIM study (Dendritic cell immunotherapy for mesothelioma). It is an open-label, randomized, Phase II/III study in 230 adults with pleural mesothelioma to assess the efficacy and antitumor activity of MesoPher as a maintenance treatment after chemotherapy. Patients in Arm A will receive three bi-weekly injections of MesoPher with the best supportive care, plus two further injections of MesoPher at Weeks 18 and 30. Patients in Arm B will receive the best supportive care alone. Six mesothelioma referral centers in five European countries are participating in the DENIM study.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the MesoPher description, mechanism of action, dosage and administration, research and development activities in malignant pleural mesothelioma (MPM).
• Elaborated details on MesoPher regulatory milestones and other development activities have been provided in this report.
• The report also highlights the MesoPher research and development activities in MPM across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around MesoPher.
• The report contains forecasted sales of MesoPher for MPM till 2032.
• Comprehensive coverage of the late-stage emerging therapies for MPM.
• The report also features the SWOT analysis with analyst views for MesoPher in MPM.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

MesoPher Analytical Perspective by DelveInsight

• In-depth MesoPher Market Assessment

This report provides a detailed market assessment of MesoPher for malignant pleural mesothelioma (MPM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

• MesoPher Clinical Assessment

The report provides the clinical trials information of MesoPher for MPM covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for malignant pleural mesothelioma (MPM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence MesoPher dominance.
• Other emerging products for MPM are expected to give tough market competition to MesoPher and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MesoPher in MPM.
• Our in-depth analysis of the forecasted sales data of MesoPher from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the MesoPher in MPM.

Key Questions

• What is the product type, route of administration and mechanism of action of MesoPher?
• What is the clinical trial status of the study related to MesoPher in malignant pleural mesothelioma (MPM) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the MesoPher development?
• What are the key designations that have been granted to MesoPher for MPM?
• What is the forecasted market scenario of MesoPher for MPM?
• What are the forecasted sales of MesoPher in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to MesoPher for MPM?
• Which are the late-stage emerging therapies under development for the treatment of MPM?